IXHL Incannex Healthcare Inc. - Common Stock
IXHL Instantánea de la Acción Precio, capitalización bursátil, P/E, BPA, ROE, deuda/capital, rango de 52 semanas
IXHL Gráfico del Precio de la Acción OHLCV diario con indicadores técnicos — desplace, amplíe y personalice su vista
Rendimiento a 10 años Tendencias de ingresos, beneficio neto, márgenes y BPA
Valoración Ratios P/E, P/S, P/B, EV/EBITDA: ¿está la acción cara o barata?
Rentabilidad Márgenes brutos, operativos y netos; ROE, ROA, ROIC
Salud financiera Deuda, liquidez, solvencia — solidez del balance general
Crecimiento Crecimiento de ingresos, BPA y beneficio neto: interanual, CAGR a 3 años, CAGR a 5 años
Eficiencia de capital Rotación de activos, rotación de inventario, rotación de cuentas por cobrar
IXHL Consenso de analistas Opiniones de analistas alcistas y bajistas, precio objetivo a 12 meses, potencial alcista
- Compra fuerte 2 28,6%
- Compra 4 57,1%
- Mantener 1 14,3%
- Venta 0 0,0%
- Venta fuerte 0 0,0%
Precio objetivo a 12 meses
1 analistas · 2026-08-19Historial de Ganancias EPS real vs estimado, sorpresa %, tasa de aciertos, próxima fecha de resultados
| Período | EPS Actual | EPS est. | Sorpresa |
|---|---|---|---|
| 30 de septiembre de 2026 | $-11.23 | $-0.76 | — |
| 31 de marzo de 2026 | $-11.23 | $-0.94 | -10.3% |
| 31 de diciembre de 2025 | $-22.83 | $-0.94 | -21.9% |
| 30 de septiembre de 2025 | $-22.95 | $-0.94 | -22.0% |
| 30 de junio de 2025 | $-15.30 | $-89.29 | 74.0% |
| 31 de marzo de 2025 | $-238.98 | $-22.16 | -216.8% |
Fundamentales Completos Todas las métricas por año — estado de resultados, balance general, flujo de caja
Estado de resultados 15
| Métrica | Tendencia | 2025 | 2024 |
|---|---|---|---|
| Revenue | $86.0K | $12.0K | |
| R&D Expense | $11M | $13M | |
| SG&A Expense | $13M | $17M | |
| Operating Expenses | $24M | $30M | |
| Operating Income | $-24M | $-30M | |
| Interest Income | $62.0K | $206.0K | |
| Other Non-op | $-23M | $12M | |
| Pretax Income | $-47M | $-18M | |
| Income Tax | · | $30.0K | |
| Net Income | $-47M | $-18M | |
| EPS (Basic) | $-1.35 | $-1.15 | |
| EPS (Diluted) | $-1.35 | $-1.15 | |
| Shares (Basic) | 34,454,269 | 16,164,338 | |
| Shares (Diluted) | 34,454,269 | 16,164,338 | |
| EBITDA | $-24M | $-30M |
Balance general 19
| Métrica | Tendencia | 2025 | 2024 |
|---|---|---|---|
| Cash & Equivalents | $15M | $6M | |
| Prepaid Expense | $791.0K | $507.0K | |
| Current Assets | $20M | $16M | |
| PP&E (Net) | $227.0K | $472.0K | |
| PP&E (Gross) | $495.0K | $598.0K | |
| Accum. Depreciation | $269.0K | $126.0K | |
| Total Assets | $20M | $17M | |
| Accounts Payable | · | $5M | |
| Accrued Liabilities | $661.0K | $5M | |
| Current Liabilities | $7M | $6M | |
| Capital Leases | $74.0K | $210.0K | |
| Total Liabilities | $7M | $6M | |
| Common Stock | $20.0K | $2.0K | |
| Paid-in Capital | $174M | $125M | |
| Retained Earnings | $-158M | $-111M | |
| AOCI | $-3M | $-3M | |
| Stockholders' Equity | $13M | $11M | |
| Liabilities + Equity | $20M | $17M | |
| Shares Outstanding | 6,479,333 | 17,642,832 |
Flujo de Efectivo 9
| Métrica | Tendencia | 2025 | 2024 |
|---|---|---|---|
| D&A | $246.0K | $103.0K | |
| Stock-based Comp | $3M | $9M | |
| Operating Cash Flow | $-13M | $-16M | |
| CapEx | $8.0K | $277.0K | |
| Investing Cash Flow | $-8.0K | $-277.0K | |
| Stock Issued | $48M | · | |
| Net Stock Activity | $48M | · | |
| Financing Cash Flow | $21M | · | |
| Free Cash Flow | $-13M | $-16M |
Rentabilidad 7
| Métrica | Tendencia | 2025 | 2024 |
|---|---|---|---|
| Operating Margin | -27661.6% | -250341.7% | |
| Net Margin | -54517.4% | -153825.0% | |
| Pretax Margin | -54517.4% | -153575.0% | |
| EBITDA Margin | -27661.6% | -250341.7% | |
| ROA | -250.1% | -90.4% | |
| ROE | -653.3% | -122.7% | |
| ROIC | · | -268.2% |
Liquidez y Solvencia 2
| Métrica | Tendencia | 2025 | 2024 |
|---|---|---|---|
| Current Ratio | 2.9 | 2.9 | |
| Quick Ratio | 2.2 | 1.0 |
Eficiencia 1
| Métrica | Tendencia | 2025 | 2024 |
|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 |
Tasas de Crecimiento 1
| Métrica | Tendencia | 2025 | 2024 |
|---|---|---|---|
| Revenue YoY | 616.7% | · |
Valoración (TTM) 10
| Métrica | Tendencia | 2025 | 2024 |
|---|---|---|---|
| Revenue TTM | $86.0K | $12.0K | |
| Net Income TTM | $-47M | $-18M | |
| Market Cap | $42M | $47M | |
| P/E | -0.2 | -2.6 | |
| P/S | 488.2 | 3888.9 | |
| P/B | 3.1 | 4.2 | |
| P / Tangible Book | 3.1 | 4.2 | |
| P / Cash Flow | -3.4 | -2.9 | |
| P / FCF | -3.4 | -2.9 | |
| Earnings Yield | -625.0% | -39.1% |
Estado de resultados 14
| Métrica | Tendencia | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | · | $0 | · | $12.0K | $74.0K | |
| R&D Expense | $321.0K | $2M | $1M | $4M | $3M | $1M | $3M | |
| SG&A Expense | $4M | $5M | $6M | $4M | $2M | $4M | $3M | |
| Operating Expenses | $4M | $7M | $7M | $8M | $5M | $5M | $6M | |
| Operating Income | $-4M | $-7M | $-7M | $-8M | $-5M | $-5M | $-6M | |
| Interest Income | · | · | · | $2.0K | $4.0K | $28.0K | $28.0K | |
| Other Non-op | $165.0K | $474.0K | $387.0K | $-24M | $1M | $-890.0K | $834.0K | |
| Pretax Income | $-4M | $-7M | $-6M | $-32M | $-4M | $-6M | $-5M | |
| Net Income | $-4M | $-7M | $-6M | $-32M | $-4M | $-6M | $-5M | |
| EPS (Basic) | $-0.35 | $-0.02 | $-0.02 | $-0.53 | $-6.19 | $-0.33 | $-0.29 | |
| EPS (Diluted) | $-0.35 | $-0.02 | $-0.02 | $-0.53 | $-6.19 | $-0.33 | $-0.29 | |
| Shares (Basic) | 12,348,460 | 349,464,317 | 310,309,659 | -20,445,524 | 654,418 | 17,624,422 | 17,642,832 | |
| Shares (Diluted) | 12,348,460 | 349,464,317 | 310,309,659 | -20,445,524 | 654,418 | 17,624,422 | 17,642,832 | |
| EBITDA | $-4M | $-7M | $-7M | · | $-5M | $-5M | $-6M |
Balance general 21
| Métrica | Tendencia | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $74M | $69M | $73M | $15M | $7M | $2M | $4M | |
| Prepaid Expense | $405.0K | $431.0K | $486.0K | $791.0K | $416.0K | $417.0K | $489.0K | |
| Current Assets | $80M | $75M | $78M | $20M | $16M | $11M | $15M | |
| PP&E (Net) | $47.0K | $108.0K | $168.0K | $227.0K | $277.0K | $273.0K | $428.0K | |
| PP&E (Gross) | $572.0K | $506.0K | $503.0K | $495.0K | $597.0K | $560.0K | $625.0K | |
| Accum. Depreciation | $525.0K | $398.0K | $335.0K | $269.0K | $320.0K | $287.0K | $197.0K | |
| Total Assets | $80M | $75M | $79M | $20M | $16M | $11M | $16M | |
| Accrued Liabilities | $202.0K | $133.0K | $154.0K | $661.0K | $4M | $3M | $7M | |
| Short-term Debt | · | · | · | · | $1M | $1M | · | |
| Current Liabilities | $2M | $2M | $2M | $7M | $7M | $6M | $9M | |
| Capital Leases | $42.0K | $53.0K | $64.0K | $74.0K | $104.0K | $152.0K | $221.0K | |
| Total Liabilities | $5M | $2M | $2M | $7M | $9M | $10M | $9M | |
| Long-term Debt | · | · | · | · | · | $2M | · | |
| Total Debt | · | · | · | · | $1M | $4M | · | |
| Common Stock | $41.0K | $36.0K | $35.0K | $20.0K | $2.0K | $2.0K | $2.0K | |
| Paid-in Capital | $253M | $247M | $244M | $174M | $137M | $126M | $126M | |
| Retained Earnings | $-174M | $-170M | $-164M | $-158M | $-126M | $-122M | $-116M | |
| AOCI | $-4M | $-3M | $-3M | $-3M | $-3M | $-3M | $-3M | |
| Stockholders' Equity | $75M | $73M | $77M | $13M | $7M | $965.0K | $7M | |
| Liabilities + Equity | $80M | $75M | $79M | $20M | $16M | $11M | $16M | |
| Shares Outstanding | 13,683,121 | 359,218,871 | 347,705,507 | 194,379,996 | 17,785,235 | 17,785,235 | 17,642,832 |
Flujo de Efectivo 11
| Métrica | Tendencia | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|---|---|
| D&A | $65.0K | $59.0K | $66.0K | $61.0K | $-5.0K | $126.0K | $64.0K | |
| Stock-based Comp | $1M | $2M | $3M | $1M | $417.0K | $435.0K | $459.0K | |
| Operating Cash Flow | $-2M | $-5M | $-9M | $-1M | $-3M | $-6M | $-2M | |
| CapEx | $5.0K | $4.0K | $2.0K | $0 | $0 | · | · | |
| Investing Cash Flow | $-18.0K | $-4.0K | $-42.0K | $0 | $0 | · | · | |
| Stock Issued | $7M | $2M | $69M | $36M | · | · | · | |
| Stock Repurchased | $1M | · | · | · | · | · | · | |
| Net Stock Activity | · | · | $69M | · | · | · | · | |
| Financing Cash Flow | $5M | $927.0K | $67M | $10M | $8M | $4M | · | |
| Net Change in Cash | · | · | · | · | · | · | $-2M | |
| Free Cash Flow | · | · | $-9M | · | · | · | · |
Rentabilidad 6
| Métrica | Tendencia | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | · | · | · | · | · | -41700.0% | -8451.3% | |
| Net Margin | · | · | · | · | · | -49116.7% | -7324.3% | |
| Pretax Margin | · | · | · | · | · | -49116.7% | -7324.3% | |
| EBITDA Margin | · | · | · | · | · | -41700.0% | -8451.3% | |
| ROA | -8.1% | -15.2% | -13.5% | · | -23.7% | -35.2% | -67.5% | |
| ROE | -9.4% | -17.5% | -15.3% | · | -36.8% | -59.4% | -164.4% |
Liquidez y Solvencia 4
| Métrica | Tendencia | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 41.6 | 48.3 | 47.5 | · | 2.1 | 1.8 | 1.6 | |
| Quick Ratio | 38.6 | 44.5 | 44.5 | · | 0.9 | 0.4 | 0.4 | |
| Debt / Equity | · | · | · | · | 0.2 | 3.9 | · | |
| LT Debt / Equity | · | · | · | · | · | 2.5 | · |
Eficiencia 1
| Métrica | Tendencia | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|---|---|
| Asset Turnover | · | · | · | · | · | 0.0 | 0.0 |
Valoración (TTM) 10
| Métrica | Tendencia | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-21M | $-23M | $-22M | · | $-21M | $-23M | $-17M | |
| Market Cap | $41M | $129M | $161M | · | $12M | $38M | $35M | |
| Enterprise Value | · | · | · | · | $7M | $39M | · | |
| P/E | -0.5 | -0.6 | -0.6 | · | -0.6 | -1.6 | -1.8 | |
| P/B | 0.5 | 1.8 | 2.1 | · | 1.6 | 39.1 | 5.3 | |
| P / Tangible Book | 0.5 | 1.8 | 2.1 | · | 1.6 | 39.1 | 5.3 | |
| P / Cash Flow | · | · | -17.6 | · | · | · | -16.0 | |
| P / FCF | · | · | -17.6 | · | · | · | · | |
| EV / EBITDA | · | · | · | · | -1.3 | -7.9 | · | |
| Earnings Yield | -219.3% | -159.2% | -181.0% | · | -177.2% | -62.7% | -54.3% |
Estados Financieros Estado de resultados, balance general, flujo de caja — anual, últimos 5 años
Estado de resultados
| 2025-06-30 | 2024-06-30 | 2023-06-30 | |
|---|---|---|---|
| Ingresos | $86.0K | $12.0K | — |
| Margen Operativo % | -27661.6% | -250341.7% | — |
| Beneficio neto | $-47M | $-18M | $-49M |
| EPS Diluido | $-1.35 | $-1.15 | $-3.32 |
Balance general
| 2025-06-30 | 2024-06-30 | 2023-06-30 | |
|---|---|---|---|
| Ratio corriente | 2.9 | 2.9 | — |
| Ratio Rápido | 2.2 | 1.0 | — |
Flujo de Efectivo
| 2025-06-30 | 2024-06-30 | 2023-06-30 | |
|---|---|---|---|
| Flujo de caja libre | $-13M | $-16M | — |
Mis Métricas Tu lista de seguimiento personal — filas seleccionadas de Fundamentales Completos
Elige las métricas que te importan — haz clic en el ➕ junto a cualquier fila en Fundamentales Completos arriba.
Tu selección se guarda y te sigue en todos los tickers.
Propietarios institucionales (13F) 1 declarante · $22 total · A fecha de 30 de junio de 2025
Instituciones que informan tener esta acción en su Formulario 13F trimestral de la SEC. Solo posiciones largas; un solo presentador puede aparecer dos veces para tramos de opciones separados. Las patas de put/call de compensación grandes suelen reflejar la creación de mercado o el inventario cubierto, no la convicción direccional.
| Nuevas posiciones | Posiciones cerradas | Aumentado | Disminuido | Cambio neto de acciones |
|---|---|---|---|---|
| 0 | 26 | 0 | 1 | — |
Comparado con Q4 2025. Las presentaciones del Formulario 13F de la SEC vencen dentro de los 45 días posteriores al final del trimestre, más un pequeño margen para los presentadores tardíos; los trimestres que aún se encuentran dentro de esa ventana se omiten en favor del par más reciente completamente reportado. Cambio vs trimestre anterior no mostrado: la cobertura de los presentadores difiere demasiado entre estos dos trimestres para una comparación fiable.
| Institución | Valor | Acciones | % de 13F rastreadas | Tipo |
|---|---|---|---|---|
| Iron Horse Wealth Management, LLC | $22 | 100 | 100,00% | Acciones |
Informantes de la empresa 7 insiders · 3 directivos · 5 consejeros
| Insider | Rol | Última actividad | Acciones en propiedad | Compras 12m | Ventas 12m | Neto 12m |
|---|---|---|---|---|---|---|
| Joel Latham | CEO and President | 14 de noviembre de 2025 A | 24 186 177 | 0 | 0 | $0 |
| Joseph Swan | CFO, Treasurer and Secretary | 14 de noviembre de 2025 A | 921 358 | 0 | 0 | $0 |
| Luigi M. Barbato | Chief Medical Officer | 23 de octubre de 2024 A | 100 476 | 0 | 0 | $0 |
| Troy Valentine | Consejero | 14 de noviembre de 2025 A | 12 001 858 | 0 | 0 | $0 |
| Robert Clark | Consejero | 14 de noviembre de 2025 A | 1 786 956 | 0 | 0 | $0 |
| Peter Widdows | Consejero | 14 de noviembre de 2025 A | 1 957 803 | 0 | 0 | $0 |
| George Anastassov | Consejero | 14 de noviembre de 2025 A | 2 456 677 | 0 | 0 | $0 |
Informantes de las presentaciones SEC Form 3/4/5; neto = solo P/S de mercado abierto